SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older
SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox)
SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy
SHINGRIX is supplied as 2 components: A single-dose vial of lyophilized gE antigen component (brown cap) and a single-dose vial of adjuvant suspension component (blue-green cap) (packaged without syringes or needles)
A single dose after reconstitution is 0.5 mL
Administer 2 doses (0.5 mL each) at 0 and 2 to 6 months
10 Doses
Manufacturer # 58160082311
Brand Shingrix®
Manufacturer Glaxo Smith Kline
Country of Origin Unknown
Application Shingles Vaccine
Container Type Single-Dose Vial
Dosage Form Injection
Generic Drug Code 43989
Generic Drug Name Zoster Vaccine Recombinant, Adjuvanted
Is_Active_Vendor Y
Is_DSCSA Y
Is_Discontinued N
Is_Medical_Device Y
Lot_Tracking_Flag Y
NDC Number 58160082311
On_Allocation N
Product Dating McKesson Acceptable Dating: we will ship >= 180 days
Storage Requirements Requires Refrigeration
Strength 50 mcg / 0.5 mL
Supplier_ID 488095
Type Intramuscular
UNSPSC Code 51201600
User Indicated for People 50 Years of Age and Older
Volume 0.5 mL
